 |
PDBsum entry 4bky
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Structural insight into maternal embryonic leucine zipper kinase (melk) conformation and inhibition toward structure-Based drug design.
|
 |
|
Authors
|
 |
G.Canevari,
S.Re depaolini,
U.Cucchi,
J.A.Bertrand,
E.Casale,
C.Perrera,
B.Forte,
P.Carpinelli,
E.R.Felder.
|
 |
|
Ref.
|
 |
Biochemistry, 2013,
52,
6380-6387.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Maternal embryonic leucine zipper kinase (MELK) is upregulated in several types
of tumor, including breast, prostate, and brain tumors. Its expression is
generally associated with cell survival, cell proliferation, and resistance to
apoptosis. Therefore, the potential of MELK inhibitors as therapeutic agents is
recently attracting considerable interest. Here we report the first structures
of MELK in complex with AMP-PNP and with nanomolar inhibitors. Our studies shed
light on the role of the MELK UBA domain, provide a characterization of the
kinase active site, and identify key residues for achieving high potency, laying
the groundwork for structure-based drug design efforts.
|
 |
|
|
|
|
 |